HCMT
APLS

Highland Capital Management (Tennessee)’s Apellis Pharmaceuticals APLS Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,133
Closed -$1.13M – 413
2025
Q3 		$1.13M Buy
+50,133
New +$1.17M 0.06% 243

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Highland Capital Management (Tennessee)'s APLS Position: Q4 2025 in Review

Highland Capital Management (Tennessee) sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 50,133 shares — an estimated $1.13M sold.

Highland Capital Management (Tennessee) first reported a position in APLS in Q3 2025 and held it in 1 quarter. The position peaked at $1.13M in Q3 2025. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • Highland Capital Management (Tennessee) reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Highland Capital Management (Tennessee) sold 50,133 Apellis Pharmaceuticals shares in Q4 2025, an estimated $1.13M.
  • Highland Capital Management (Tennessee) first reported a position in Apellis Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Highland Capital Management (Tennessee)'s Apellis Pharmaceuticals position peaked at $1.13M in Q3 2025.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q4 2025, filed 2 Feb 2026.